TY - JOUR
AU - Lodde, Georg C
AU - Hassel, Jessica
AU - Wulfken, Lena M
AU - Meier, Friedegund
AU - Mohr, Peter
AU - Kähler, Katharina
AU - Hauschild, Axel
AU - Schilling, Bastian
AU - Loquai, Carmen
AU - Berking, Carola
AU - Hüning, Svea
AU - Eckardt, Julia
AU - Gutzmer, Ralf
AU - Reinhardt, Lydia
AU - Glutsch, Valerie
AU - Nikfarjam, Ulrike
AU - Erdmann, Michael
AU - Beckmann, Catharina L
AU - Stang, Andreas
AU - Kowall, Bernd
AU - Galetzka, Wolfgang
AU - Roesch, Alexander
AU - Ugurel, Selma
AU - Zimmer, Lisa
AU - Schadendorf, Dirk
AU - Forschner, Andrea
AU - Livingstone, Elisabeth
TI - Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
JO - European journal of cancer
VL - 191
SN - 0014-2964
CY - Amsterdam [u.a.]
PB - Elsevier
M1 - DKFZ-2023-01494
SP - 112957
PY - 2023
AB - Clinical trials demonstrated significantly improved recurrence-free survival (RFS) of melanoma patients receiving adjuvant treatment. As data from controlled trials are based on selected populations, we investigated adjuvantly treated stage III melanoma patients under real-world conditions.In a prior multicenter cohort study, stage III-IV melanoma patients were analysed for their choice of adjuvant therapy. In this follow-up study, we examined RFS, overall and melanoma-specific survival (MSS) and response to the subsequent treatment of 589 stage III patients (232 BRAF-mutated) receiving adjuvant PD-1 inhibitors (PD1; n = 479) or targeted therapy (TT; n = 110).The median follow-up of the total cohort was 25.7 months. The main reason for premature discontinuation of adjuvant therapy was disease progression in PD1- (28.8
KW - Adjuvant treatment (Other)
KW - BRAF (Other)
KW - Immunotherapy (Other)
KW - Melanoma (Other)
KW - PD1 (Other)
KW - Real-world (Other)
KW - Targeted therapy (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:37487400
DO - DOI:10.1016/j.ejca.2023.112957
UR - https://inrepo02.dkfz.de/record/277779
ER -